# Avance Biosciences: Analytical and Bioanalytical Solutions Empowering Drug Development and Manufacturing > Avance Biosciences is a leading Contract Research Organization \(CRO\) and Contract Testing Organization \(CTO\) providing CGMP and GLP\-compliant analytical Generated by Yoast SEO v28.0, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [Avance Biosciences Contract Research Organization \- About Us](https://www.avancebio.com/about/): Avance Biosciences is a premier CRO and CTO delivering CGMP/GLP\-compliant analytical and bioanalytical services, method development, validation, and testing to accelerate drug development and manufacturing worldwide\.\.\. - [Contact Avance Biosciences](https://www.avancebio.com/contact-us/): Our highly experienced scientists, quality professionals and biotechnology service experts are here to assist you with all your drug development and manufacturing support needs\.\.\. - [Terms of Use](https://www.avancebio.com/about/terms-of-use/) - [Privacy](https://www.avancebio.com/about/privacy/) - [Cell Therapies \- Analytical Testing Services](https://www.avancebio.com/modality/cell-gene-therapy/): Avance Biosciences provides CGMP\- and GLP\-compliant testing services for cell therapies, including CAR\-T and stem cells, delivering analytical and bioanalytical support from development through clinical trials and commercialization\.\.\. - [Gene Therapy \- Analytical Testing Services](https://www.avancebio.com/modality/gene-therapies/): Avance Biosciences provides comprehensive gene therapy analysis services, delivering GLP/CGMP\-compliant analytical and bioanalytical testing for viral vectors, plasmids, and mRNA therapies across development, clinical, and CMC stages\.\.\. - [Preclinical Gene Editing Analysis](https://www.avancebio.com/services-3/preclinical-studies/gene-editing-profiling/): Gene editing analysis evaluates on\- and off\-target stability to ensure safe, effective gene and cell therapies\. Avance Biosciences applies NGS amplicon sequencing, ddPCR, and qPCR to deliver regulatory\-ready preclinical and clinical PK/PD data\.\.\. - [Analytical Services for mAb, ADC, and Protein Drugs](https://www.avancebio.com/modality/biologics/): Avance Biosciences provides comprehensive analytical services for mAbs, ADCs, and protein drugs, delivering genomics, proteomics, and immunoassay support across preclinical, clinical, and CMC stages to ensure safety, quality, and efficacy\.\.\. - [Vaccines \- Analytical Services for Vaccine Development](https://www.avancebio.com/modality/vaccines/): Avance Biosciences delivers comprehensive analytical services for vaccine development, including mRNA vaccines, providing genomics, proteomics, and immunoassay support across preclinical, clinical, and CMC stages to ensure safety, efficacy, and quality\.\.\. - [Small Molecule Drugs \- Bioanalytical Services for Small Molecule Drug Development](https://www.avancebio.com/modality/small-molecule-drugs/): Avance Biosciences provides bioanalytical services for small molecule drugs, using genomics and proteomics to analyze gene and protein expression and support PK/PD, biomarker studies, and regulatory\-ready preclinical and clinical development\.\.\. - [CGMP/GLP\-Compliant Next Generation DNA Sequencing Services](https://www.avancebio.com/tecchnology/next-generation-sequencing-ngs-center-of-excellence/next-gen-sequencing-service/): Next\-generation DNA sequencing enables genomic profiling, biomarker discovery, and characterization across drug and gene therapy development\. Avance Biosciences delivers CGMP/GLP\-compliant NGS using advanced platforms for validated, regulatory\-ready results\.\.\. - [Next\-Generation Sequencing \(NGS\) Center of Excellence](https://www.avancebio.com/tecchnology/next-generation-sequencing-ngs-center-of-excellence/): Avance Biosciences’ NGS Center of Excellence delivers CGMP/GLP\-compliant sequencing across Illumina, PacBio, Nanopore, AVITI, and 10x Genomics to support vector characterization, CRISPR analysis, biodistribution, and other regulatory\-ready biopharmaceutical development\.\.\. - [Potency Assay Development Services for CMC Support](https://www.avancebio.com/services-3/cmc-support/potency-assay-development/): Potency assay services evaluate the biological activity of cell and gene therapies to meet IND and BLA requirements\. Avance Biosciences designs, validates, and runs custom GMP potency assays using advanced bioanalytical technologies\.\.\. - [Analytical Support for mRNA Therapeutics](https://www.avancebio.com/services-3/cmc-support/mrna-ds-dp-testing/): Analytical support for mRNA therapeutics ensures identity, purity, potency, and stability of mRNA vaccines and products\. Avance Biosciences delivers CGMP DS/DP testing, including sequencing, RT\-qPCR, impurity, encapsulation, and sterility assays for release readiness\.\.\. - [DNA Biodistribution Studies for Biopharma Drug Development](https://www.avancebio.com/services-3/preclinical-studies/dna-biodistribution-study/): Biodistribution studies assess the distribution and persistence of gene vectors and therapeutic cells using qPCR and ddPCR to evaluate safety and efficacy\. Avance Biosciences designs and executes GLP and non\-GLP assays with proven workflows for reliable, high\-quality results\.\.\. - [Immunogenicity Testing Services for Biopharma Drug Development](https://www.avancebio.com/services-3/preclinical-studies/ada-studies-immunogenicity-testing-new-style/): Immunogenicity testing evaluates immune responses and anti\-drug antibodies to ensure biologic safety and efficacy\. Avance Biosciences designs multi\-tiered ADA and NAb assays using advanced methods to deliver regulatory\-ready preclinical and clinical data\.\.\. ## Posts - [FDA Issues Draft Guidance on Genome Editing Safety Assessment Using NGS](https://www.avancebio.com/fda-issues-draft-guidance-on-genome-editing-safety-assessment-using-ngs/): The FDA’s new draft guidance on genome editing safety marks a significant step toward more standardized, data\-driven evaluation of gene therapies\. With next\-generation sequencing \(NGS\) at the core, the guidance outlines clear expectations for assessing off\-target effects, genomic integrity, and rare editing events, providing sponsors with a more defined regulatory path for IND and BLA submissions\. - [GUIDE\-seq and NGS\-based off\-target analysis support genome editing safety assessment for engineered Treg therapy](https://www.avancebio.com/gentibio-presents-comprehensive-genome-safety-data-during-on-and-off-target-method-development-session-at-asgct/) - [Avance Biosciences to Exhibit at the ASGCT 2026 Annual Meeting](https://www.avancebio.com/avance-biosciences-to-exhibit-at-the-asgct-2026-annual-meeting/): Avance Biosciences will be exhibiting at the ASGCT Annual Meeting in Boston, May 11–15, 2026\. Visit Booth \#1062 to connect with our team and learn how our bioanalytical and CMC testing services support cell and gene therapy development\[\.\.\.\] - [Avance Biosciences Launches Potency \& Cell\-Based Assay Center in Houston](https://www.avancebio.com/avance-biosciences-launches-potency-cell-based-assay-center-in-houston/): HOUSTON, December 3, 2025 /PRNewswire/ — Avance Biosciences today announced the opening of its new Potency and Cell\-Based Assay Center of Excellence, a purpose\-built facility designed to expand and centralize the company's capabilities in potency and functional cell\-based assays under GMP compliance \[\.\.\.\] - [FDA’s New Plausible Mechanism Pathway: How It Compares to Existing Approval Routes](https://www.avancebio.com/fdas-new-plausible-mechanism-pathway-how-it-compares-to-existing-approval-routes/): Explore the FDA’s new Plausible Mechanism Pathway and how it compares to accelerated approval, expedited programs, and other regulatory routes for rare disease therapies\. ## Optional - [Sitemap index](https://www.avancebio.com/sitemap_index.xml)